Pulmonary manifestations of systemic lupus erythematosus

Seminars in Respiratory and Critical Care Medicine

Volumn 35, Issue 2, 2014, Pages 249-254

  Mittoo, Shikha ^a   Fell, Charlene D ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

airways; lung; pleura; systemic lupus erythematosus; vascular

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOUBLE STRANDED DNA ANTIBODY; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOLIPID ANTIBODY; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; SM ANTIBODY; VASODILATOR AGENT; AUTOANTIBODY;

ARTICLE; BRONCHIECTASIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CRACKLE; CYANOSIS; DIFFUSE ALVEOLAR HEMORRHAGE; DYSPNEA; HEART CATHETERIZATION; HOARSENESS; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG DISEASE; LUNG FUNCTION; LUNG HEMORRHAGE; LUNG INFECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUPUS PNEUMONITIS; PATHOGENESIS; PLASMAPHERESIS; PLEURA EFFUSION; PLEURISY; PLEURODESIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RESPIRATORY FUNCTION; RESTRICTIVE LUNG DISEASE; SHRINKING LUNG SYNDROME; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSTHORACIC ECHOCARDIOGRAPHY; COMPLICATION; IMMUNOLOGY; LUNG DISEASES; PATHOPHYSIOLOGY; THROMBOEMBOLISM;

AUTOANTIBODIES; HUMANS; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLEURISY; PROGNOSIS; THROMBOEMBOLISM;

EID: 84897061233     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1371537     Document Type: Article

References (51)

1. Pines A., Kaplinsky N., Olchovsky D., Rozenman J., Frankl O. Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications. Chest: 1985; 88 1 129 135 (Pubitemid 15073591)
2. Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol: 2012; 2012 854941
3. Badesch D. B., Abman S. H., Ahearn G. S., et al. American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest: 2004; 126 (1, Suppl): 35S 62S (Pubitemid 38932341)
4. Kamel S. R., Omar G. M., Darwish A. F., Asklany H. T., Ellabban A. S. Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord: 2011; 4 77 86
5. Luo Y. F., Robbins I. M., Karatas M., Brixey A. G., Rice T. W., Light R. W. Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chest: 2011; 140 1 42 47
6. Lian F., Chen D., Wang Y., et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int: 2012; 32 6 1727 1731
7. Scofield R. H., Tardibono G., Ogden S. B., Harley J. B., Reichlin M., Kurien B. T. Rheumatoid hyperviscosity: analysis of a patient with intermediate complexes that block other autoantibodies and a review of the literature. Semin Arthritis Rheum: 1998; 27 6 382 391 (Pubitemid 28298351)
8. Kishida Y., Kanai Y., Kuramochi S., Hosoda Y. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol: 1993; 20 12 2161 2162 (Pubitemid 24043147)
9. Galiè N., Hoeper M. M., Humbert M., et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J: 2009; 30 20 2493 2537
10. Swigris J. J., Fischer A., Gillis J., Meehan R. T., Brown K. K. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest: 2008; 133 1 271 280
11. Chow S. L., Chandran V., Fazelzad R., Johnson S. R. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. Lupus: 2012; 21 4 353 364
12. Condliffe R., Kiely D. G., Peacock A. J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med: 2009; 179 2 151 157
13. Fishbein G. A., Fishbein M. C. Lung vasculitis and alveolar hemorrhage: pathology. Semin Respir Crit Care Med: 2011; 32 3 254 263
14. Chen G. X., Dong Y., Ju Z. B. [A clinical analysis of 32 patients with diffuse alveolar hemorrhage in diffuse connective tissue diseases]. Zhonghua Nei Ke Za Zhi: 2008; 47 5 362 365
15. Martínez-Martínez M. U., Abud-Mendoza C. Predictors of mortality in diffuse alveolar haemorrhage associated with systemic lupus erythematosus. Lupus: 2011; 20 6 568 574
16. Narshi C. B., Haider S., Ford C. M., Isenberg D. A., Giles I. P. Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford): 2010; 49 2 392 394
17. Mittoo S., Fischer A., Strand V., Meehan R., Swigris J. J. Systemic lupus erythematosus-related interstitial lung disease. Curr Rheumatol Rev: 2010; 6 2 99 107
18. Quadrelli S. A., Alvarez C., Arce S. C., et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus: 2009; 18 12 1053 1060
19. Hellman D. B., Kirsch C. M., Whiting-O'Keefe Q., et al. Dyspnea in ambulatory patients with SLE: prevalence, severity, and correlation with incremental exercise testing. J Rheumatol: 1995; 22 3 455 461
20. Eisenberg H., Dubois E. L., Sherwin R. P., Balchum O. J. Diffuse interstitial lung disease in systemic lupus erythematosus. Ann Intern Med: 1973; 79 1 37 45
21. ter Borg E. J., Groen H., Horst G., Limburg P. C., Wouda A. A., Kallenberg C. G. Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum: 1990; 20 3 164 173
22. Ward M. M., Polisson R. P. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum: 1989; 32 10 1226 1232 (Pubitemid 19261073)
23. Matthay R. A., Schwarz M. I., Petty T. L., et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore): 1975; 54 5 397 409
24. Groen H., ter Borg E. J., Postma D. S., Wouda A. A., van der Mark T. W., Kallenberg C. G. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med: 1992; 93 6 619 627
25. Silberstein S. L., Barland P., Grayzel A. I., Koerner S. K. Pulmonary dysfunction in systemic lupus erythematosus: prevalence classification and correlation with other organ involvement. J Rheumatol: 1980; 7 2 187 195 (Pubitemid 11222932)
26. Andonopoulos A. P., Constantopoulos S. H., Galanopoulou V., Drosos A. A., Acritidis N. C., Moutsopoulos H. M. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest: 1988; 94 2 312 315
27. Nakano M., Hasegawa H., Takada T., et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology: 2002; 7 1 45 49 (Pubitemid 34856894)
28. Rolla G., Brussino L., Bertero M. T., Bucca C., Converso M., Caligaris-Cappio F. Respiratory function in systemic lupus erythematosus: relation with activity and severity. Lupus: 1996; 5 1 38 43 (Pubitemid 26072427)
29. Rolla G., Brussino L., Bertero M. T., et al. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rheumatol: 1997; 24 6 1066 1071 (Pubitemid 27250110)
30. Bertoli A. MVL, Vila L. M., Apte M., et al. LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus: 2007; 16 6 410 417 (Pubitemid 47122214)
31. Carmier D., Diot E., Diot P. Shrinking lung syndrome: recognition, pathophysiology and therapeutic strategy. Expert Rev Respir Med: 2011; 5 1 33 39
32. Tan E. MCA, Cohen A. S., Fries J. F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum: 1982; 25 11 1271 1277 (Pubitemid 13221242)
33. Cervera R., Abarca-Costalago M., Abramovicz D., et al. European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the Euro-Lupus Project Autoimmun Rev: 2006; 5 3 180 186 (Pubitemid 43234182)
34. Mittoo S., Gelber A. C., Hitchon C. A., et al. Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Clinical and serologic factors associated with lupus pleuritis. J Rheumatol: 2010; 37 4 747 753
35. Boddaert J., Huong D. L., Amoura Z., Wechsler B., Godeau P., Piette J. C. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore): 2004; 83 6 348 359 (Pubitemid 39541112)
36. Badui E., Garcia-Rubi D., Robles E., et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology: 1985; 36 7 431 441 (Pubitemid 15247819)
37. Toworakul C., Kasitanon N., Sukitawut W., Wichinun R., Louthrenoo W. Usefulness of pleural effusion antinuclear antibodies in the diagnosis of lupus pleuritis. Lupus: 2011; 20 10 1042 1046
38. Winslow W. A., Ploss L. N., Loitman B. Pleuritis in systemic lupus erythematosus: its importance as an early manifestation in diagnosis. Ann Intern Med: 1958; 49 1 70 88
39. Glazer M., Berkman N., Lafair J. S., Kramer M. R. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest: 2000; 117 5 1404 1409
40. Karim A., Ahmed S., Siddiqui R., Marder G. S., Mattana J. Severe upper airway obstruction from cricoarytenoiditis as the sole presenting manifestation of a systemic lupus erythematosus flare. Chest: 2002; 121 3 990 993 (Pubitemid 34251471)
41. Fenlon H. M., Doran M., Sant S. M., Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol: 1996; 166 2 301 307 (Pubitemid 26036286)
42. Hariri L. P., Unizony S., Stone J., et al. Acute fibrinous and organizing pneumonia in systemic lupus erythematosus: a case report and review of the literature. Pathol Int: 2010; 60 11 755 759
43. Kawahata K., Yamaguchi M., Kanda H., et al. Severe airflow limitation in two patients with systemic lupus erythematosus: effect of inhalation of anticholinergics. Mod Rheumatol: 2008; 18 1 52 56
44. Godeau B., Cormier C., Menkes C. J. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis: 1991; 50 12 956 958
45. Bernatsky S., Boivin J. F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum: 2006; 54 8 2550 2557 (Pubitemid 44205016)
46. Kinder B. W., Freemer M. M., King T. E. Jr., et al. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum: 2007; 56 8 2679 2686 (Pubitemid 47237286)
47. Gladman D. D., Hussain F., Ibañez D., Urowitz M. B. The nature and outcome of infection in systemic lupus erythematosus. Lupus: 2002; 11 4 234 239 (Pubitemid 34506728)
48. Weng C. T., Liu M. F., Weng M. Y., et al. Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from southern Taiwan. J Clin Rheumatol: 2013; 19 5 252 258
49. Bin J., Bernatsky S., Gordon C., et al. Lung cancer in systemic lupus erythematosus. Lung Cancer: 2007; 56 3 303 306 (Pubitemid 46679081)
50. Bernatsky S., Joseph L., Boivin J. F., et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis: 2008; 67 1 74 79
51. Artinian V., Kvale P. A. Cancer and interstitial lung disease. Curr Opin Pulm Med: 2004; 10 5 425 434 (Pubitemid 39099941)